Corneal cross-linking: fifteen years of progress towards theranostic monitoring

Fifteen years of iontophoresis-assisted cross-linking without epithelial removal, progressing towards theranostic monitoring of riboflavin and treatment effect.

Dr Clair-Florent Schmitt-Bernard in the operating theatre with three generations of corneal cross-linking devices
Dr Clair-Florent Schmitt-Bernard with three generations of cross-linking devices, from early protocols to theranostic monitoring.

Three generations of devices

A recently published Instagram post looks back on fifteen years of corneal cross-linking for progressive keratoconus. Three generations of devices represent the transition from early protocols to optimised procedures and then to theranostic monitoring. This timeline is a professional account, not a clinical comparison of the devices.

What theranostic monitoring measures

Cross-linking combines riboflavin with controlled ultraviolet A irradiation to increase corneal biomechanical resistance. Its purpose is to slow objectively documented keratoconus progression. Theranostic monitoring adds optical measurements during treatment: the studied device estimates corneal riboflavin concentration, monitors its UVA-mediated photodegradation and calculates a score intended to estimate treatment effect during the procedure. [1–3]

Exclusive use of iontophoresis in my practice

In my practice, cross-linking is performed exclusively with iontophoresis and without epithelial removal. A low-intensity electrical current delivers riboflavin through an intact epithelium. Avoiding a central epithelial wound markedly reduces risks specifically related to de-epithelialisation — substantial pain, delayed healing, surface infection and haze — and usually allows a faster return towards the pre-procedure level of vision. It does not remove every risk of cross-linking or the need for long-term tomographic follow-up. [5–7]

What the first clinical data show

A multicentre randomised clinical trial in 50 patients assessed whether the combined riboflavin and theranostic scores could predict Kmax flattening at one year. The trial provides favourable clinical evidence, but it remains limited in size and concerns a defined device, protocols and thresholds. It should not be interpreted as a guarantee of individual stabilisation. [3]

A useful measurement with limitations

The measurement is based on riboflavin fluorescence. A 2026 critical paper notes that this optical signal may also be influenced by light scattering, absorption, hydration and tissue changes during irradiation. The score is therefore a device-specific intraoperative indicator; serial corneal topography or tomography remains necessary to assess actual keratoconus progression. [4]

Fifteen years of collaboration

The post also refers to long-term collaboration with Horus Pharma and Clinique Saint-Roch in Montpellier. This professional history is presented as one of progress, measurement and procedural personalisation, without changing the indications for cross-linking or the requirements for patient selection and follow-up.